Kornimate/medical-research-clean huggingface dataset:
effects of treadmill training on motor function, balance, and spasticity reduction in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: this study investigates the impact of treadmill training on motor function, balance, and spasticity reduction in children with cerebral palsy (cp). the study synthesizes existing research to provide insights into the effectiveness of treadmill training as an intervention for improving these key outcomes in children with cerebral palsy

cerebral palsy is a neurodevelopmental disorder characterized by impaired movement and posture due to non-progressive brain damage occurring before, during, or shortly after birth.this systematic review and meta-analysis comprehensively examines the effects of treadmill training on motor function, balance, and spasticity reduction in children diagnosed with cerebral palsy (cp). the review includes studies published in peer-reviewed journals, databases, and relevant conference proceedings. inclusion criteria encompass randomized controlled trials, quasi-experimental studies, and cohort studies evaluating treadmill training interventions in children aged 2-18 years with cp. studies utilizing various treadmill training protocols, such as body-weight-supported treadmill training, overground treadmill training, or virtual reality-assisted treadmill training, are considered. the primary outcomes assessed include changes in motor function, as measured by standardized assessment tools like the gross motor function measure (gmfm) or the movement assessment battery for children (mabc). additionally, balance improvements are evaluated using validated balance assessment scales, while spasticity reduction is measured through clinical assessments, such as the modified ashworth scale (mas) or the tardieu scale. the review aims to provide evidence-based insights into the efficacy of treadmill training as a rehabilitation intervention for children with cp, informing clinical practice guidelines and therapeutic decision-making. the findings contribute to our understanding of the potential benefits of treadmill training in improving motor function, balance, and spasticity in this

Eligibility criteria:
inclusion criteria: * age 4 -12 years. * children having, i-ii on gmfcm. * children diagnosed with spastic cerebral palsy. * children with will cognitive behavior exclusion criteria: * misdiagnosed or not conform to cerebral palsy. * children should be medically un stable uncontrolled seizures * the children with mental retardation or other neurological disorders. * children with serve respiratory dysfunction, multiple contracture. * children with prior undone this type of training. * children with taking medication like muscle relaxant. * children having communication or hearing issues.
effects of manual therapy on the upper cervical spine combined with exercise vs isolated exercise in patients with cervicogenic headache.

Conditions: Cervicogenic Headache; Headache

Summary: cervicogenic headache is defined as unilateral headache associated with neck pain. effect of manual translatoric therapy of the upper cervical spine associated with cervical exercises in these patients is currently unknown. our aim was to determine if adding manual therapy to an exercise and home-exercise program improved effects on symptoms and function in short- and mid-term in patients with cervicogenic headache. a randomized controlled study will be conducted with 40 subjects with cervicogenic headache. each group will receive four 20-minute sessions weekly and a home-exercise program. upper cervical flexion, flexion-rotation test, impact headache test-6 (hit-6), headache intensity, craniocervical flexion test, pain pressure thresholds and global rating of change (groc)-scale will be assessed at end of the intervention, at 3- and at 6-month follow-ups.


Eligibility criteria:
inclusion criteria: * diagnosis of cervicogenic headache according to sjaastad et al. subjects will have to fulfill both parts i and iii of the major criteria for diagnosis (pain aggravated by neck movement, sustained position or external pressure, restricted cervical range of motion, and unilateral pain starting in the neck and radiating to the frontotemporal region) * hypomobility in one or more segments of c0-1, c1-2, c2-3 through manual evaluation. * a positive result in the flexion-rotation test. * a failure to pass stage 2 (24 mmhg) of the craniocervical flexion test. * be at least 18 years old. * have signed the informed consent. exclusion criteria: * contraindications for manual therapy or exercise. * participation in exercise or manual therapy programs in the last three months. * inability to maintain supine position. * the use of pacemakers (the magnets in the crom device could alter their signal). * inability to perform the flexion-rotation test. * language difficulties. * pending litigation or lawsuits.

Keywords: cervicogenic headache exercise manual therapy upper cervical spine
cli and far for intraoperative margin assessment

Conditions: Breast Cancer Female

Summary: this study is a prospective, single arm interventional study to evaluate the diagnostic accuracy of intraoperative cerenkov luminescence imaging (cli) plus flexible autoradiography (far) using the lightpath® imaging system for intraoperative tumour margin assessment compared to post-operative standard-of-care histopathology in women undergoing breast-conserving surgery for breast cancer.

the intraoperative lightpath images will be used to inform the operating surgeon about potentially detectable cancer at the margins of the excised specimen in an attempt to achieve better guided cancer surgery and complete tumour excision with clear resection margins. if a positive excision margin is detected on intraoperative lightpath® images, the operating surgeon will take a cavity shaving of the corresponding margin, provided more tissue can be taken. subsequent lightpath® imaging of the cavity shaving will inform the operating surgeon on the margin status of the shaving. if a positive excision margin is detected on intraoperative lightpath® images, the operating surgeon will take a further cavity shave of the corresponding margin, provided more tissue can be taken. the resection margin status of the wle specimen and cavity shavings (if any), as assessed by lightpath cli + far imaging will be compared with final histopathology results. a positive margin on histology will be defined as * invasive carcinoma: positive: \<1mm; negative ≥1mm * ductal carcinoma in situ (dcis) (if present): positive: \<2mm; negative ≥2mm.

Eligibility criteria:
inclusion criteria: * • female subjects ≥18 years of age with a diagnosis of invasive breast cancer scheduled to undergo bcs * subjects who are able to give voluntary, written informed consent to participate in this study * subjects who are able to understand this study and are willing to complete all the study assessments * female subjects of childbearing age must have a negative pregnancy test (by beta human chorionic gonadotrophin (β-hcg) qualitative analysis) or must have had a history of a surgical sterilisation or must give history of no menses in the past twelve months. exclusion criteria: * subjects who have had surgery to the ipsilateral breast in the past 12 months * subjects who have had radiotherapy to the ipsilateral breast * subjects who have a known hypersensitivity to 18f-fdg * subjects who are pregnant or lactating * subjects who have an existing medical condition that would compromise their participation in the study
a study of the effect of ono-8539 on oesophageal pain hypersensitivity in patients with non-erosive reflux disease

Conditions: GERD

Summary: a random controlled study to investigate the effect of a new drug, ono-8539, on oesophageal pain hypersensitivity in patients with gastric reflux disease

this is a randomised, double-blind, placebo-controlled, two-period crossover study to investigate the effect of ono-8539 on oesophageal pain hypersensitivity in patients with non-erosive reflux disease

Eligibility criteria:
inclusion criteria: * male and female subjects aged 18-70 years inclusive with confirmed gerd and normal oesophageal mucosa will be enrolled in this study. subjects demonstrate moderate intensity heartburn while being on a stable dose of proton pump inhibitor and demonstrate oesophageal hypersensitivity following distal oesophageal acid perfusion. exclusion criteria: * subjects will be excluded if they have a motility disorder, are not able to tolerate study procedures or have had gi surgery or have a condition that would affect the study results. subjects with functional heartburn, acute gi symptoms, endoscopic or manometric abnormality or a protocol-specified cardiovascular condition will not be enrolled.

Keywords: gerd
non-exposure simple suturing eftr (ness-eftr) with laparoscopic sentinel lymph node navigation for egc (senorita3-phase 2)

Conditions: Early Gastric Cancer

Summary: laparoscopic sentinel lymph node dissection and stomach preserving surgery in early gastric cancer is less invasive method which can increase quality of life. current stomach preserving surgery after sentinel lymph node dissection produce transmural communication and expose the tumor to the peritoneum during operation. an endoscopic full-thickness resection method with a simple suturing technique that does not expose the gastric mucosa to the peritoneum (non-exposure simple suturing endoscopic full-thickness resection, ness-eftr) was recently developed. this is the phase2 study to identify the efficacy of ness-eftr with sentinel node navigation in early gastric cancer patients.


Eligibility criteria:
inclusion criteria: * single lesion of adenocarcinoma in preoperative endoscopic biopsy * clinical stage t1n0 in the preoperative evaluation of endoscopy and computed tomography * tumor size: less than 3cm * location: 3cm far from the pylorus or cardia * aged 20 to 80 * ecog 0 or 1 * patient who signed the agreement * patient who is suspected to underwent laparoscopy assisted gastrectomy exclusion criteria: * absolute indication of endoscopic submucosal resection * inoperable due to poor cardiac, pulmonary function * pregnant * having allergic reaction, previous upper abdominal surgery except laparoscopic cholecystectomy, previous radiation therapy to upper abdomen * diagnosed as malignancy within 5 years except carcinoma in situ of cervix cancer and thyroid cancer
maraviroc versus etravirine in combination with antiretroviral therapy in drug experienced hiv and hepatitis co-infected patients

Conditions: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic

Summary: confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in hiv and hepatitis co-infected patients.


Eligibility criteria:
inclusion criteria: hiv-1 rna viral load of ≥1000 copies/ml at the screening visit. detectable hcv rna levels or hepatitis b surface antigen (hbsag) positive. previous antiretroviral treatment experience with at least 2 antiretroviral drug classes for ≥3 months. documented resistance to an nnrti as well as documented resistance to another antiretroviral agent. ccr5 tropic virus detected by the trofiletm assay. exclusion criteria: suspected or documented active, untreated hiv-1 related opportunistic infection (oi) or other condition requiring acute therapy at the time of randomization (subjects on a stable (\>1 month) secondary oi prophylaxis regimen are eligible for the study; subjects on a primary oi prophylaxis regimen of any duration are also eligible for the study). prior treatment with darunavir/ritonavir, raltegravir, or another integrase inhibitor, etravirine, maraviroc or another ccr5 inhibitor for more than 14 days at any time. subjects receiving treatment for chronic hepatitis or the expected need to initiate hcv treatment within 48 weeks of randomization. (subjects who were previously treated for hepatitis c are eligible for the study). ast and/or alt greater than 5 times the upper limit of normal (actg grade 3).

Keywords: hiv and hepatitis co-infection
reducing breathlessness with dronabinol in copd patients

Conditions: COPD; Breathlessness; Cannabis

Summary: this clinical trial examines whether dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (thc), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (copd).

this study is a randomized, controlled, double-blind, crossover trial evaluating the effectiveness of the pharmaceutical drug dronabinol in patients with severe and very severe copd. the researchers will compare the effects of dronabinol with a placebo (an identical-looking substance that contains no active drug) to determine if dronabinol reduces breathlessness in copd patients. after enrollment, study subjects will undergo four weeks of treatment with both dronabinol and the placebo in a blinded and randomized sequence. there is a two-week washout period between treatments. during these treatment phases, subjects will complete questionnaires about their daily experiences of breathlessness and wear a watch that records various health parameters. the study includes eight visits: the initial enrollment and follow-up checks every two weeks. at these visits, subjects undergo tests for lung function and walking distance, and complete health status questionnaires. additionally, blood samples for thc levels and hair samples for cortisol analysis are collected.

Eligibility criteria:
inclusion criteria: * refractory dyspnea despite optimal treatment * copd (gold 3,4) * breathlessness corresponding to mmrc score ≥ 3 * informed written consent * age ≥ 18 years * cognitive relevant, of legal age * understands and speaks danish * for fertile women defined by amenorrhea for less than 12 months: negative hcg before entry into the trial * for fertile and sexually active subjects: use of safe contraception during medication intake and 4 weeks after: intrauterine device (iud) or hormonal contraception (oral contraceptive pill, implant, transdermal patch, vaginal ring or depot injection). exclusion criteria: * ongoing infection or exacerbation of copd within the last month (30 days) * regular treatment with thc or cbd within 1 month (30 days) * life expectancy less than 3 months (90 days) * treatment with medicines that, according to the summary of product characteristics, are strong inhibitors or inducers of cyp3a4, cyp2c9 or cyp2c19 * history of or current evidence of significant medical or psychiatric disorder that is considered by the investigator to put the subject at greater risk of experiencing an adverse event * current or past substance abuse where the investigator finds it too risky for the subject to be included in the study

Keywords: randomized, controlled, double-blind, crossover trial cannabis-based medicine cannabis copd breathlessness
the presence of a therapy dog reduces pain and anxiety during pediatric elbow pin removal

Conditions: Elbow Injury

Summary: the purpose of this research study is to assess whether the presence of therapy dogs can reduce pain and anxiety in children ages 3 to 10 having pins removed from their elbow.

this procedure is done in an outpatient clinic 3-4 weeks after the pins are placed and can be uncomfortable and cause anxiety in some patients. therapy dogs are trained to sit calmly with a patient on or near the exam table as a distraction from procedures.

Eligibility criteria:
inclusion criteria: * presenting to clinic for elbow pin removal post elbow fracture surgery exclusion criteria: * dog allergy * fear of dogs
neuroscience of psychotherapy for depression

Conditions: Depression

Summary: the goal of this study is to learn the extent to which client-therapist brain activity may synchronize during a psychosocial intervention for depression symptoms. the study will compare behavioral activation, a client-centered type of cognitive-behavioral therapy, to psychoeducation which delivers information on strategies to recover from depression symptoms. participants will answer questions about their mental and physical health, attend one psychosocial intervention session receiving either behavioral activation or psychoeducation with simultaneous brain activity measurement and complete follow up surveys two weeks and one month following the intervention.

this is a pilot study to investigate the neuroscience of a single-session psychosocial intervention for depression symptoms. brain activity is measured with eeg in both research participant and therapist. participants will fill in questionnaires about their depression symptoms and experience during the psychosocial intervention.

Eligibility criteria:
inclusion criteria for participants/clients: * between ages 18 and 30 * full-time student status (undergraduate, graduate, and professional) * experience mild to moderate depressive symptoms as determined by the beck depression inventory (score: 14-28) * no current suicidal ideation, score of 0 on columbia-suicide severity rating scale (c-ssrs in past month) * capacity to understand study procedures (informed consent) * ability to speak and understand english * willingness to comply with study procedures inclusion criteria for therapists: * ages 18 or older * qualification to administer therapy (decided by the principal investigator) * capacity to understand the study procedures (informed consent) * speak and understand english * willingness to comply with study procedures exclusion criteria for participants/clients: * active, current suicidal ideation as determined by the columbia-suicide severity rating scale (c-ssrs) in the past month * past suicidal attempt (lifetime) * recently initiated psychotherapy (past month) * elevated psychosis risk based on self-report prodromal questionnaire - brief version (pq-b) or self-reported diagnosis of psychotic disorder by mental health provider * positive screen for autism spectrum disorder based on the self-report autism quotient (aq-10) or self-reported diagnosis of autism spectrum disorder by mental health provider, * daily intake of benzodiazepine of \>20 mg diazepam milligram equivalent * inability to give informed, voluntary, written consent to participate * inability to effectively communicate in english as determined by interaction with study personnel * anything else that in the assessment of the study team is not conducive to the successful completion of the study requirements. there are no exclusion criteria for therapists

Keywords: eeg hyperscanning therapeutic alliance psychoeducation behavioral activation
robot-assisted stair climbing training

Conditions: Stroke

Summary: stair climbing up and down is an essential part of everyday's mobility. physiotherapy is focused on muscle strengthening, real floor walking and stairs climbing tasks, but these methods do not stress in terms of intensity stair-climbing practice. the aims of this study is to compare whether an intensive robot-assisted stair climbing training (rasct) is more effective than conventional physiotherapy (cp) for improving stair climbing ability, gait and postural control in stroke patients.

trial design: a pilot randomized (allocation ratio 1:1), single blind clinical trial (rct) comparing the effects between the experimental \[robot-assisted stair climbing training group (rasct)\] and control group (conventional physiotherapy, cp) in improving stair climbing ability and postural control in stroke patients. the examiner will be blind to group assignment.

Eligibility criteria:
inclusion criteria: * first-ever ischemic or hemorrhagic stroke; * more than or equal to 3 months post stroke; * age\>18 years; * mini- mental state examination (mmse) score more than 23; * ability to stand for at least 1 min without arm support; ability to walk independently for at least 10 m with or without walking aids; * functional ambulation category score equal or more than 1. * signed informed consent form exclusion criteria: * severe cognitive or communicative disorders that hamper collaboration; * unstable cardiovascular system conditions (i.e. labile compensated cardiac insufficiency, angina pectoris), deep vein thrombosis, severe neurological or orthopedic diseases which massively affect lower limb mobility; severe joint misalignment; * treatment of lower limb spasticity (i.e. botulinum toxin) in the 3 months prior to the start of the study and/or during its execution.

Keywords: balance, gait, rehabilitation, stroke, robotics, postural
modulation of adjuvant 5-fu by folinic acid and interferon-alpha in colon cancer

Conditions: Rectal Cancer

Summary: the primary objective was to improve adjuvant 5-fu chemoradiotherapy in resectable rectal cancer. the investigators hypothesis was that modulation of 5-fu by addition of either fa or inf-alpha may increase overall survival.

primary endpoint was overall survival (os). for sample size estimation the following assumptions were made: the 5-year os rate of 5-fu was estimated to be 58%. our intention was to detect an increase in the 5-year os rate by one of the additives of at least 10% with a power of 80% and a level of significance of 5% in comparison to 5-fu (one-sided). hypotheses were analyzed as pair wise comparisons between the treatment options. this resulted in a target sample size of 280 patients per group and a total of 840 patients.

Eligibility criteria:
inclusion criteria: * eligibility was defined as potentially curative en-bloc resection (r0) of an adenocarcinoma of the rectum with a lower tumor edge within 12 cm from the anal verge determined by rectoscopy, a pathologic uicc stage ii (pt3/4pn0m0) or iii (pt1-4pnposm0) with examination of at least 12 lymph nodes, a white blood count ≥ 3,500/µl, a platelet count ≥ 100,000/µl, a ecog performance status of 0 or 1, and written informed consent. exclusion criteria: * ineligible were patients not fulfilling these criteria or having a history of cancer except for adequately treated superficial basal or squamous cell skin cancer or in situ carcinoma of the cervix, getting previous radio- or chemotherapy, pregnant or nursing women, other having severe concomitant diseases limiting life expectancy or not allowing chemotherapy, and with social conditions not allowing a 5-year follow-up.

Keywords: rectal cancer adjuvant chemoradiotherapy 5-fu, interferon-alpha locally advanced resectable rectal cancer (uicc stage ii and iii)
anatomic congruent prosthetic knee design

Conditions: Knee Osteoarthritis

Summary: this double-blinded randomized control study will use kinematic and kinetic measures to compare an anatomical congruent prosthetic knee design to a standard prosthetic knee design. the patients will be measured pre- and post-operative and compared to a healthy non-osteoarthritis control group.


Eligibility criteria:
inclusion criteria: * informed and written consent. * primary knee osteoarthritis in capable men and women. * indication for cruciate-retaining total knee arthroplasty. exclusion criteria: * patients who do not speak and read danish. * patients who are pregnant or at risk of becoming pregnant during the project. * patients with active cancer and/or radiation or chemotherapy. * patients who are alcoholics or have some form of abuse that impede information and follow-up. * patients with severe psychiatric disease that might complicate compliance with follow-up. * patients with surgically implants in the affected leg and/or pace maker. * patients with greater thigh circumference then 60 cm. * patients cannot perform the described exercises. * patients with knee instability due to multiligament injury. * patients with conditions that severely compromise their gait other than knee osteoarthritis in the affected knee. * patients with severe fracture sequelae or severe malalignment at knee level. * patients with osteosynthesised fractures using bone graft at knee level. * patients with need of an augmentation and/or stem-elongation. * patients with metabolic bone disease. * patients with rheumatoid arthritis.